In the September 10, 2022, the audience was treated to a wondrous ALK fusion discussion, including a real-world case discussion of a stage 4 non-small cell lung cancer (NSCLC) patient with 2 ALK fusions.
The HUTCHMED pipeline was highlighted as savolitinib, surufatinib, fruquintinib, tazemetostat, sovleplenib, amdizalisib, HMPL-453, HPML-306, HPBL-295, HMPL-760, HMPL-653, and HMPL-A83 were discussed. During this there was a conversation of approved BTK, IDH 1/2, FGFR 1/2/3, and SYK inhibitors. We did speak of the toxicity concerns regarding PI3K delta inhibitors, such as amdizalisib, including how idelalisib, umbralisib, and duvelisib were pulled off the market. We talked about how CD47 inhibitors have become much maligned.
We reviewed the new fruquintinib data that may lead to its approval in stage 4 colorectal cancer.
During the patient case, we talked about ALK resistance mechanism and MET amplification in this setting. We discussed the use of combination therapy and focused on HSP90 inhibitors.
Due to time constraints we pushed our incredible MET Ex14 case and discussion to the September 24, 2022, tumor board..
An incredible analysis of the stage 4 double ALK FUSION stage 4 non-small cell lung cancer (NSCLC) patient was performed in the context of the COMET algorithm and treatment cartography. All presently FDA-approved non-small cell lung cancer treatments were discussed, including the data that led to their approval.
Clinical trials in the stage 4 ALK fusion non-small cell lung cancer space were depicted.
NOBODY HAS DONE WHAT WAS DONE IN THIS TUMOR BOARD OR THE FOUR PRIOR RCIMTB TUMOR BOARDS. MSK, MD Anderson, Johns Hopkins, Mayo, etc., are not doing what is being done here, but they should be.
If you don't believe that, PLEASE SEE FOR YOURSELF.
This tumor board was hosted by:
Basem S. Goueli MD, PhD, MBA (co-host): CEO and Founder of CancerLight, Cancer Clarity, and Revolution Cancer Medical Care PLLC, medical director for 2 Xbiotech trials, full-time GENERAL hematologist/oncologist, consultant for numerous companies, writer of "The Insider's Guide to Translational Medicine" on biopharmatrend.com and "The Cancer Patients Don't Have an Expiration Date Series" on revolutioncancer.com, author and speaker of the "If You Were My Family Member" cancer patient education series on revolutioncancer.com and this channel
Janakiraman Subramanian MD (co-host): Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI), and Director for ISCI Data and Analytics Research Core.
Silambarasan Maskomani Ph.D. (co-host): Personalized healthcare ecosystem partner for Roche, where he is currently helping build a precision oncology program in India.
It featured:
Ali Ucar: CEO and co-founder of CaresolutionsUSA
14 окт 2024
